U.S. markets open in 7 hours 31 minutes

BGI Genomics Co., Ltd. (300676.SZ)

Shenzhen - Shenzhen Delayed Price. Currency in CNY
Add to watchlist
118.52-0.91 (-0.76%)
As of 1:44PM CST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close119.43
Bid118.48 x 0
Ask118.52 x 0
Day's Range117.50 - 120.00
52 Week Range110.97 - 199.40
Avg. Volume3,698,213
Market Cap49.057B
Beta (5Y Monthly)0.53
PE Ratio (TTM)19.22
EPS (TTM)6.17
Earnings DateApr 26, 2021
Forward Dividend & Yield0.10 (0.09%)
Ex-Dividend DateJul 07, 2020
1y Target Est100.77
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      Chinese state fund invests in gene firm BGI

      The Chinese government has made an investment in BGI Genomics Co, a listed Chinese company that has supplied millions of COVID-19 tests globally as the gene firm seeks to fund exponential growth driven by the pandemic. BGI Group, which runs a massive gene databank in China and has DNA sequencing contracts with health firms and universities worldwide, has in the past responded to claims from U.S. security agencies that it is closely linked to the Chinese government by saying it has no Chinese government capital. BGI Genomics, the company's subsidiary listed on the Shenzhen stock exchange, raised the equivalent of just over $300 million in a private placement to investors including China's biggest state investment vehicle, the State Development and Investment Corp (SDIC), filings to the exchange on Feb. 1 show.

    • China's BGI forecasts 700% jump in first-half profit due to COVID-19 test kit demand

      China's BGI forecasts 700% jump in first-half profit due to COVID-19 test kit demand

      China's BGI Genomics Co said on Tuesday it expects first-half net profit to be about eight times the amount reported in the same period last year after the global pandemic created a surge in demand for its coronavirus test kits. The genomics company, which said it has distributed more than 35 million kits across 180 countries and regions, forecasted a net profit of between 1.53 to 1.63 billion yuan ($218.32-$232.66 million) in the six months to end-June, a jump of around 700% from 198 million yuan a year ago. The novel coronavirus, which first emerged in China late last year, has to date infected over 13 million people globally and killed more than 575,000.